Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- METI Report Calls For Free Competition for Medical, Nursing Care Services
February 26, 2001
- BUSINESS NEWS IN BRIEF -1-
February 26, 2001
- Elimination of NHI Price SystemShould Be Considered: Prof. Tokita
February 26, 2001
- REGULATORY NEWS IN BRIEF
February 26, 2001
- WORLD BUSINESS NEWS IN BRIEF
February 26, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 26, 2001
- New Law Specific for Medical Devices Is Necessary: JFITMA President
February 26, 2001
- Kirin to Sponsor Genomic Medical Engineering Course at Tottori Univ.
February 26, 2001
- New ARIA Guidelines Prepared by WHO for Allergic Rhinitis
February 26, 2001
- Big Internet Influence on Pharma Fields Predicted: Mr Tanimura of So-net M3
February 26, 2001
- Strategies of AdvaMed, EUCOMED for Japan Revealed
February 26, 2001
- Suzuken to Quit Nursing Home Business
February 26, 2001
- OTC NEWS IN BRIEF
February 26, 2001
- BUSINESS NEWS IN BRIEF -2-
February 26, 2001
- Sysmex Expands Its Development Base in Europe
February 26, 2001
- Chuikyo Subcommittee Starts Discussions on Drug Prices
February 26, 2001
- Reorganization to Push New Drugs into Orbit as Soon as Possible: Mr Nakashima of Tanabe
February 26, 2001
- Chugai's '75-year History' Published
February 19, 2001
- Standard Drug Name, Lab Test Masters Completed
February 19, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
February 19, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…